Lisa Astor

Identifying a number of cancer predisposition genes could help improve upon risk assessment and counseling for ductal carcinoma in situ and contralateral breast cancer.

Chimeric antigen receptor T-cell therapy is one such newer class of therapy to be introduced into the treatment paradigm for multiple myeloma, and bispecific antibodies are the expected next class of treatments to emerge in the clinic.

Currently, there are few treatment options for patients with polycythemia vera that can help to control hematocrit levels and reduce the need for phlebotomy and the incidence of thrombosis.

Positive findings were reported from the phase 2 ARNEO trial during the European Association of Urology Congress 2022.

Adjuvant pembrolizumab continues to demonstrate these impressive results with disease-free survival in renal cell carcinoma, according to Thomas Powles, MD, MBBS, MRCP.

A presentation at ESMO 2022 explains the use of circulating tumor DNA as a tool which can predict outcomes for patients with diffuse large B-cell lymphoma.

During the Annual Meeting of the International Society of Gastrointestinal Oncology, experts in the field and investigators from pivotal studies will elucidate how these advances can be used to guide treatment, and how to choose between available treatments in specific patient populations.

Two genes to assist in determining primary resistance to immunotherapy for patients with mismatch repair–deficient/microsatellite instability–high gastrointestinal cancers have been identified.

Patients with relapsed or refractory multiple myeloma who relapsed after treatment with B-cell maturation antigen–directed chimeric antigen receptor T-cell therapy.

In findings presented at the ESMO World Congress on Gastrointestinal Cancer 2022, patients with intrahepatic and extrahepatic cholangiocarcinoma who were treated with the durvalumab triplet regimen demonstrated improved overall survival compared with the chemotherapy doublet.

New findings suggest that all patients with lung cancer undergo germline testing.

Investigators continue to explore possible systemic treatment options that could improve disease control for patients with brain metastases derived from breast cancer.

The use of endocrine therapy as single agents serves as the control arm for many clinical studies seeking to improve upon outcomes with combination regimens and newer agents for patients with HR-positive, HER2-negative advanced breast cancer.

Treatment with relacorilant showed improvement in overall survival in patients platinum-resistant or platinum-refractory ovarian cancer when combined with nab-paclitaxel.

Several treatment options are being explored for patients who have residual disease or who relapse after CAR T-cell therapy, including a possible second infusion with the same CAR T-cell product.

Bevacizumab improved progression-free survival and overall survival when added to frontline chemotherapy in patients with advanced ovarian clear cell carcinoma, according to a retrospective analysis of patients treated in Japan from 2008 to 2018.

Improvement in overall survival shown in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab, according to results from the phase 3 PARADIGM trial.

Treatment with ribociclib and an alternate endocrine therapy after progression on a prior CDK4/6 inhibitor improved progression-free survival over placebo and endocrine therapy in patients with HR-positive, HER2-negative unresectable or metastatic breast cancer, according to results of the randomized phase 2 MAINTAIN trial.

Findings from an arm of the EPCORE NHL-2 trial, presented at the 2022 ASCO Annual meeting, showed promising antitumor activity in patients with relapsed or refractory follicular lymphoma on subcutaneous epcoritamab combined with rituximab and lenalidomide.

The FDA has approved pegfilgrastim-pbbk, a biosimilar product referencing Neulasta.

Oritinib demonstrated almost complete disease control in previously treated patients with EGFR T790M–mutant, locally advanced or metastatic non–small cell lung cancer.

Results from the CameL-sq clinical trial support camrelizumab plus chemotherapy as a standard first-line treatment option for advanced squamous non–small cell lung cancer, according to Caicun Zhou, MD, PhD.

Niraparib in combination with abiraterone acetate, and prednisone resulted in a composite response in more than half of all patients.

The phase 1a/b NEBULA trial is investigating the safety and preliminary efficacy of the adenoviral vector NG-641 in combination with nivolumab in patients with previously treated metastatic or advanced epithelial tumors.

Research results suggest that CAR T-cell therapy can overcome T cell defects caused by chronic lymphocytic leukemia, with remissions possibly lasting more than a decade for patients with significant disease burden when treated with CD4+ CAR T cells

Over the past decade, cancer regimens featuring CTLA-4 inhibitor monotherapy have largely been replaced by combination regimens pairing these agents with anti–PD-1/ PD-L1 antibodies.

The future of myelofibrosis may include several JAK inhibitor treatment niches as well as combination regimens with JAK inhibition in both the upfront and second-line setting and more, according to John Mascarenhas, MD.

In acute myeloid leukemia, ongoing clinical trials are exploring the potential of this checkpoint alone or as part of a dual immunotherapy regimen.

Positive phase 1 results of TQ-B2450 combined with anlotinib have lead to a phase 3 study of the combination versus pembrolizumab in patient with PD-L1 positive advanced non–small cell lung cancer.

Findings from the phase 1/2 IPH2201-203 trial support the statement that monalizumab, cetuximab, and durvalumab show promising activity in patients with recurrent squamous cell carcinoma of the head and neck.